These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26620317)

  • 1. Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease.
    Jin L; Wang R; Zhu Y; Zheng W; Han Y; Guo F; Ye FB; Li Y
    Sci Rep; 2015 Dec; 5():17288. PubMed ID: 26620317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
    Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
    Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
    Wang J; Yang N; Xu Y
    Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists.
    Shen T; Shi A; Wei Y; Luo X; Xi L
    Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.
    Xiong X; Wang X; Lu Y; Wang E; Zhang Z; Yang J; Zhang H; Li X
    J Hepatol; 2014 Apr; 60(4):847-54. PubMed ID: 24333182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
    Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
    Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
    Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
    Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
    Seok S; Sun H; Kim YC; Kemper B; Kemper JK
    Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FXR controls CHOP expression in steatohepatitis.
    Fuchs CD; Claudel T; Scharnagl H; Stojakovic T; Trauner M
    FEBS Lett; 2017 Oct; 591(20):3360-3368. PubMed ID: 28895119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Sanyal AJ
    Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
    Carr RM; Reid AE
    Curr Atheroscler Rep; 2015 Apr; 17(4):500. PubMed ID: 25690590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism.
    Jin L; Feng X; Rong H; Pan Z; Inaba Y; Qiu L; Zheng W; Lin S; Wang R; Wang Z; Wang S; Liu H; Li S; Xie W; Li Y
    Nat Commun; 2013; 4():1937. PubMed ID: 23728580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
    Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of FDA-approved drugs targeting the Farnesoid X Receptor.
    van de Wiel SMW; Bijsmans ITGW; van Mil SWC; van de Graaf SFJ
    Sci Rep; 2019 Feb; 9(1):2193. PubMed ID: 30778102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
    Kim SG; Kim BK; Kim K; Fang S
    Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
    Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
    Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.